ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

por Giavina-Bianchi, Pedro, Cua, Eric, Risso, Karine, Mondain, Véronique, Vissian, Anaïs, Joie, Cécile, Pouletty, Philippe, Gineste, Paul, Ehrlich, Hartmut J., Kalil, Jorge
Publicado 2023